Francesca Hoehne, MD
General Surgery · Bakersfield, CANPI 1093725442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $291 and has fallen 65.4% since, to $101 in 2025.
Across 65 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$208
- Eisai Inc.$114
- Medtronic$79
- Daiichi Sankyo Inc.$72
- E.r. Squibb & Sons, L.L.C.$66
- Johnson & Johnson$63
- plus $659 from 23 others
What the payments were for
- Food & beverage$1,261100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 10 | $208 |
| Eisai Inc. | 7 | $114 |
| Medtronic | 2 | $79 |
| Daiichi Sankyo Inc. | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Johnson & Johnson(2 entities) | 2 | $63 |
| AstraZeneca | 4 | $59 |
| Novartis | 3 | $55 |
| Dendreon Pharmaceuticals LLC | 3 | $53 |
| Genentech USA, Inc. | 2 | $47 |
| Bayer | 3 | $44 |
| Incyte Corporation | 2 | $42 |
| Merck | 2 | $41 |
| Sanofi | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Pfizer | 2 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Myovant Sciences Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| AbbVie | 1 | $18 |
| Seagen Inc. | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Smith+Nephew | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Exelixis Inc. | 1 | $11 |
How this compares
$1,261 in reported general payments places this provider in the 80th percentile of 167 general surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other general surgery in Bakersfield
- Tanya AnandBakersfield$3K
- Daniel SwartzFresno$83K
- Daniel MarcusMarina del Rey$43K
- Brian PalafoxOrange$40K
- Houshmand NaimLos Angeles$33K
- Carlos CorveraSan Francisco$25K
- Stevan ClarkLos Angeles$16K
- Yeong AhnLos Angeles$12K
- Jane KakkisFountain Valley$12K
- Michael DeveraLoma Linda$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.